Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
Gaujoux S, Pinson S, Gimenez-Roqueplo AP, Amar L, Ragazzon B, Launay P, Meatchi T, Libé R, Bertagna X, Audebourg A, Zucman-Rossi J, Tissier F, Bertherat J. Gaujoux S, et al. Among authors: bertagna x. Clin Cancer Res. 2010 Nov 1;16(21):5133-41. doi: 10.1158/1078-0432.CCR-10-1497. Epub 2010 Oct 26. Clin Cancer Res. 2010. PMID: 20978149
Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré AM, René-Corail F, Jullian E, Gicquel C, Bertagna X, Vacher-Lavenu MC, Perret C, Bertherat J. Tissier F, et al. Among authors: bertagna x. Cancer Res. 2005 Sep 1;65(17):7622-7. doi: 10.1158/0008-5472.CAN-05-0593. Cancer Res. 2005. PMID: 16140927
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.
Libé R, Fratticci A, Coste J, Tissier F, Horvath A, Ragazzon B, Rene-Corail F, Groussin L, Bertagna X, Raffin-Sanson ML, Stratakis CA, Bertherat J. Libé R, et al. Among authors: bertagna x. Clin Cancer Res. 2008 Jun 15;14(12):4016-24. doi: 10.1158/1078-0432.CCR-08-0106. Clin Cancer Res. 2008. PMID: 18559625 Free PMC article.
Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
Gaujoux S, Tissier F, Groussin L, Libé R, Ragazzon B, Launay P, Audebourg A, Dousset B, Bertagna X, Bertherat J. Gaujoux S, et al. Among authors: bertagna x. J Clin Endocrinol Metab. 2008 Oct;93(10):4135-40. doi: 10.1210/jc.2008-0631. Epub 2008 Jul 22. J Clin Endocrinol Metab. 2008. PMID: 18647815
Pathogenesis of adrenocortical cancer.
Bertherat J, Bertagna X. Bertherat J, et al. Among authors: bertagna x. Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):261-71. doi: 10.1016/j.beem.2008.10.006. Best Pract Res Clin Endocrinol Metab. 2009. PMID: 19500768 Review.
Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, Libé R, René-Corail F, Audebourg A, Vacher-Lavenu MC, Groussin L, Bertagna X, Dousset B, Bertherat J, Tissier F. Bonnet S, et al. Among authors: bertagna x. J Clin Endocrinol Metab. 2011 Feb;96(2):E419-26. doi: 10.1210/jc.2010-1885. Epub 2010 Nov 17. J Clin Endocrinol Metab. 2011. PMID: 21084400
β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma.
Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libé R, Chokri I, Audebourg A, Royer B, Sbiera S, Vacher-Lavenu MC, Dousset B, Bertagna X, Allolio B, Bertherat J, Tissier F. Gaujoux S, et al. Among authors: bertagna x. Clin Cancer Res. 2011 Jan 15;17(2):328-36. doi: 10.1158/1078-0432.CCR-10-2006. Epub 2010 Nov 18. Clin Cancer Res. 2011. PMID: 21088256
Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.
Ragazzon B, Libé R, Assié G, Tissier F, Barreau O, Houdayer C, Perlemoine K, Audebourg A, Clauser E, René-Corail F, Bertagna X, Dousset B, Bertherat J, Groussin L. Ragazzon B, et al. Among authors: bertagna x. Eur J Endocrinol. 2014 Feb 4;170(3):385-91. doi: 10.1530/EJE-13-0778. Print 2014 Mar. Eur J Endocrinol. 2014. PMID: 24347427
293 results